VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ — Mapmygenome announced the completion of its acquisition of Vancouver-based dnaPower Inc., a pioneer in personal genomics. The strategic transaction expands Mapmygenome’s North American footprint and establishes a market-leading platform in DNA testing, gut microbiome health, longevity, and AI-driven multi-omics testing.
By uniting dnaPower with Mapmygenome’s global scale and premier CAP-accredited clinical laboratory capabilities, including Vancouver-based Microbiome Insights, acquired in 2025, the acquisition creates a centralized platform for DNA, microbiome, pharmacogenetic, and longevity testing dedicated to proactive, preventive healthcare across Canada and the US.
“Acquiring dnaPower is a pivotal step in scaling our North American operations,” said Anu Acharya, Founder and CEO of Mapmygenome. “Pairing dnaPower’s commercial trajectory with our CAP-accredited clinical laboratories and AI capabilities positions us to define the next frontier in microbiome, longevity, and precision health testing.”
“Joining Mapmygenome unlocks an extraordinary growth chapter for dnaPower,” said Dr. Lois Nahirney, Founder and CEO of dnaPower. “Backing from a global leader with elite laboratory infrastructure gives us the foundation to scale rapidly across North America, delivering advanced, high-quality products directly to our clients.”
Strategic Highlights
- Market Expansion: Integrates dnaPower’s consumer reach with Mapmygenome’s global footprint, technology stack, and R&D pipeline.
- Integrated Longevity Engine: Combines multi-omics analytics and clinical laboratory capabilities to deploy new commercial offerings in healthy aging, gut profiling, and epigenetic assessment.
- Centralized Operations: Establishes a Vancouver processing hub operating under CAP-accredited and ISO-certified protocols.
Comprehensive Testing Suite
- Longevity and Gut Health: Advanced shotgun metagenomic sequencing, gut microbiome profiling, epigenetic biological age panels, and longevity insights.
- Genomic and Preventive Health: Whole-genome and exome sequencing, pharmacogenetics, DNA wellness panels, methylation testing, and clinical bioinformatics.
About Mapmygenome
Mapmygenome is a global leader in personal genomics, longevity solutions, and precision medicine. Combining AI-driven multi-omics with premier CAP-accredited clinical laboratory infrastructure, Mapmygenome empowers individuals and healthcare providers with actionable insights across whole-genome sequencing, gut health, and healthy aging to transform preventive care worldwide.
Learn more: mapmygenome.ai
About dnaPower
Founded in 2008 and based in Vancouver, dnaPower specializes in actionable DNA-based health, nutrition, fitness, methylation, and longevity insights for consumers and practitioners.
Learn more: dnaPower.com
About Microbiome Insights
Microbiome Insights, a Mapmygenome company, is a Canadian provider of CAP-accredited DNA, microbiome, and multi-omics sequencing, analytics, and bioinformatics services.
Learn more: Microbiomeinsights.com
Media Contact
Email: anu@mapmygenome.ai
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/mapmygenome-completes-acquisition-of-dnapower-inc-to-accelerate-north-american-expansion-in-dna-microbiome-longevity-and-precision-health-testing-302915385.html
